c-RET
Les inhibiteurs de c-RET ciblent le proto-oncogène RET (Rearranged during Transfection), qui code une tyrosine kinase réceptrice impliquée dans la croissance, la différenciation et la survie cellulaire. L'activation anormale de la signalisation RET peut entraîner une prolifération cellulaire incontrôlée et une résistance à l'apoptose, contribuant au développement de cancers tels que le carcinome médullaire de la thyroïde et le cancer du poumon non à petites cellules. L'inhibition de c-RET peut induire l'apoptose dans les cellules cancéreuses et constitue une approche prometteuse dans la thérapie ciblée du cancer. Chez CymitQuimica, nous offrons une variété d'inhibiteurs de c-RET de haute qualité pour soutenir vos recherches en oncologie, transduction du signal et apoptose.
61 produits trouvés pour "c-RET"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS :BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Formule :C23H27F4N3O4SDegré de pureté :99.23%Couleur et forme :SolidMasse moléculaire :517.54Ref: TM-T10624
1mg40,00€2mg54,00€5mg92,00€10mg127,00€25mg208,00€50mg311,00€100mg445,00€1mL*10mM (DMSO)92,00€RET-IN-4
CAS :RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Formule :C27H31FN10O2Couleur et forme :SolidMasse moléculaire :546.611RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Formule :C38H42N10O3Couleur et forme :SolidMasse moléculaire :686.81YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Formule :C58H63F3N12O9Couleur et forme :SolidMasse moléculaire :1129.19AD57 (hydrochloride)
CAS :AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formule :C22H21ClF3N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :491.9RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Couleur et forme :Odour SolidCofetuzumab
CAS :Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.Degré de pureté :>95%Couleur et forme :LiquidMasse moléculaire :146.7 kDaCDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formule :C29H26N4OMasse moléculaire :446.21066RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Formule :C22H22N6OCouleur et forme :SolidMasse moléculaire :386.45PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formule :C22H22FN5O2Couleur et forme :SolidMasse moléculaire :407.44RET-IN-28
CAS :RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Formule :C26H29N9Couleur et forme :SolidMasse moléculaire :467.57Zeteletinib hemiadipate
CAS :Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Formule :C56H56F6N8O12Couleur et forme :SolidMasse moléculaire :1147.098BT44
CAS :BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Formule :C28H27F4N3O4SDegré de pureté :99.87%Couleur et forme :SoildMasse moléculaire :577.59Ref: TM-T67733
1mg74,00€5mg160,00€10mg235,00€25mg424,00€50mg635,00€100mg924,00€1mL*10mM (DMSO)188,00€QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Formule :C53H54N12O4Couleur et forme :SolidMasse moléculaire :923.07Compound TPX-0046
CAS :Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Formule :C21H21FN6O3Degré de pureté :99.94%Couleur et forme :SoildMasse moléculaire :424.43RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Formule :C40H44N10OCouleur et forme :SolidMasse moléculaire :680.84RET ligand-1
CAS :RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Formule :C28H24F2N6O3Couleur et forme :SolidMasse moléculaire :530.525trans-Pralsetinib
CAS :trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Formule :C27H32FN9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :533.6Pralsetinib
CAS :Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFormule :C27H32FN9O2Degré de pureté :97.88% - 99.8%Couleur et forme :SolidMasse moléculaire :533.6WHI-P180
CAS :WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Formule :C16H15N3O3Degré de pureté :99.21%Couleur et forme :SolidMasse moléculaire :297.31BBT594
CAS :BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Formule :C28H30F3N7O3Degré de pureté :99.57%Couleur et forme :SolidMasse moléculaire :569.58RET V804M-IN-1
CAS :RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Formule :C19H16N6ODegré de pureté :97.94% - 99.62%Couleur et forme :SolidMasse moléculaire :344.37Ref: TM-T8467
1mg35,00€2mg50,00€5mg74,00€10mg90,00€25mg157,00€50mg236,00€100mg334,00€200mg495,00€1mL*10mM (DMSO)82,00€TPX-0046
CAS :TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
Formule :C21H21FN6O3Degré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :424.43Selpercatinib
CAS :"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Formule :C29H31N7O3Degré de pureté :99.89% - >99.99%Couleur et forme :SolidMasse moléculaire :525.6Ref: TM-T8222
2mg34,00€5mg49,00€10mg84,00€25mg166,00€50mg259,00€100mg477,00€200mg692,00€500mg1.035,00€1mL*10mM (DMSO)56,00€Pyrazoloadenine
CAS :Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Formule :C5H5N5Degré de pureté :99.02%Couleur et forme :Beige PowderMasse moléculaire :135.13GSK3179106
CAS :GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nMFormule :C22H21F4N3O4Degré de pureté :99.8% - 99.90%Couleur et forme :SolidMasse moléculaire :467.41Treprostinil Sodium
CAS :Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Formule :C23H33NaO5Degré de pureté :99.67% - >99.99%Couleur et forme :SolidMasse moléculaire :412.5SPP-86
CAS :SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Formule :C16H15N5Degré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :277.32Ref: TM-T16923
1mg46,00€5mg90,00€10mg144,00€25mg281,00€50mg447,00€100mg650,00€500mg1.369,00€1mL*10mM (DMSO)90,00€WHI-P180 hydrochloride
CAS :WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Formule :C16H16ClN3O3Couleur et forme :SolidMasse moléculaire :333.77AD80
CAS :AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Formule :C22H19F4N7ODegré de pureté :99.49% - 99.75%Couleur et forme :SolidMasse moléculaire :473.43Ref: TM-T4301
1mg44,00€5mg96,00€10mg138,00€25mg268,00€50mg439,00€100mg645,00€500mg1.333,00€1mL*10mM (DMSO)90,00€RET-IN-16
CAS :RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Formule :C31H29F3N8O2Couleur et forme :SolidMasse moléculaire :602.61RET-IN-15
CAS :RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Formule :C27H28N8O2Couleur et forme :SolidMasse moléculaire :496.56RET-IN-8
CAS :RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Formule :C27H30N6O3Couleur et forme :SolidMasse moléculaire :486.57RET-IN-12
CAS :RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Formule :C30H30F3N5O4Couleur et forme :SolidMasse moléculaire :581.59RET-IN-6
CAS :RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Formule :C30H29N7Couleur et forme :SolidMasse moléculaire :487.6RET-IN-22
CAS :RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Formule :C29H31F3N6O4Couleur et forme :SolidMasse moléculaire :584.59XMD15-44
CAS :XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Formule :C29H29F3N4OCouleur et forme :SolidMasse moléculaire :506.56DUN73423
CAS :DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Formule :C19H16N6ODegré de pureté :98.09%Couleur et forme :SolidMasse moléculaire :344.37TRK II-IN-1
CAS :TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formule :C29H31F3N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :564.6RET-IN-3
CAS :RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.Formule :C18H21N5O2Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :339.39Ref: TM-T9673
1mg73,00€5mg158,00€10mg240,00€25mg452,00€50mg712,00€100mg1.093,00€200mg1.473,00€1mL*10mM (DMSO)168,00€RET-IN-23
CAS :RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Formule :C28H28FN11Degré de pureté :97.46%Couleur et forme :SolidMasse moléculaire :537.59TG-89
CAS :TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFormule :C26H34N6O3SDegré de pureté :98.68%Couleur et forme :SolidMasse moléculaire :510.65Pz-1
CAS :Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Formule :C26H26N6O2Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :454.52RET-IN-13
CAS :RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Formule :C32H33F4N5O3Couleur et forme :SolidMasse moléculaire :611.63NSC194598
CAS :NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Formule :C20H19N3OCouleur et forme :SolidMasse moléculaire :317.38FHND5071
CAS :FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFormule :C30H30D3N9OCouleur et forme :SolidMasse moléculaire :538.66FLT3/ITD-IN-4
CAS :FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Formule :C25H22N4O5Couleur et forme :SolidMasse moléculaire :458.47RET-IN-5
CAS :RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Formule :C29H26FN9OCouleur et forme :SolidMasse moléculaire :535.57RET-IN-24
CAS :RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Formule :C27H26F2N8OCouleur et forme :SolidMasse moléculaire :516.55RET-IN-25
CAS :RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFormule :C22H17N3O5SCouleur et forme :SolidMasse moléculaire :435.45RET-IN-17
CAS :RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Formule :C27H28F4N4O4Couleur et forme :SolidMasse moléculaire :548.53RET-IN-9
CAS :RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.Formule :C26H27N9OCouleur et forme :SolidMasse moléculaire :481.55LRRK2-IN-17
CAS :LRRK2-IN-17 is an orally active LRRK2 inhibitor with IC50 values of 3.5 nM for WT and 3.3 nM for G2019S, and it also inhibits RET kinase with an IC50 of 59 nM. LRRK2-IN-17 is utilized in research related to cancer and Parkinson's disease (PD).Formule :C18H18N8Couleur et forme :SolidMasse moléculaire :346.39FHND5071 (1H)
CAS :FHND5071 (1H) is a selective inhibitor of RET (rearranged during transfection) tyrosine kinase. It shows potential for research applications in RET-driven cancers, such as thyroid and lung cancer.Formule :C30H33N9OCouleur et forme :SolidMasse moléculaire :535.64TAS05567
CAS :TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).Formule :C21H29N9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.51RET-IN-30
CAS :RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. It is capable of inhibiting the proliferation of A549 cells and demonstrates antitumor properties.Formule :C26H26FN5OCouleur et forme :SolidMasse moléculaire :443.52RET-IN-10
CAS :RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).Formule :C29H28N8OSCouleur et forme :SolidMasse moléculaire :536.65RET-IN-7
CAS :RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice throughFormule :C22H24ClFN6O2Couleur et forme :SolidMasse moléculaire :458.92RET-IN-1
CAS :RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).Formule :C29H31N9O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :553.61WF-47-JS03
WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.
Formule :C30H38N6O2Couleur et forme :SolidMasse moléculaire :514.66Enbezotinib
CAS :Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Formule :C21H21FN6O3Degré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :424.43Ref: TM-T62285
1mg77,00€5mg166,00€10mg253,00€25mg414,00€50mg567,00€100mg745,00€1mL*10mM (DMSO)182,00€
